In conclusion, we identified that anti-CCP2 titers constitute an independent factor associated not only with the presence but also with the severity of RA-ILD; the relevance of these markers in patients with established ILD for future outcomes, such as progression of lung involvement and mortality, remains to be established. The gene discussed is AGBL2; the disease is rheumatoid arthritis.